A Phase 2 Study of LY3537021 for Chemotherapy-Induced Nausea and Vomiting (GIP Peptide Analog)
Eli Lilly and Company
Summary
This ongoing Phase 2 trial (n=204) evaluates LY3537021, a glucose-dependent insulinotropic peptide (GIP) analog, as add-on to standard antiemetic therapies for chemotherapy-induced nausea and vomiting (CINV) in adults receiving cisplatin or anthracycline/cyclophosphamide regimens. The primary endpoint is complete response in the delayed CINV phase (24-120 hours post-chemotherapy).
Clinical Significance
This represents a novel application of incretin-based peptides beyond metabolic disease—leveraging GIP receptor signaling for antiemetic purposes. If successful, LY3537021 could expand the therapeutic utility of incretin peptides into supportive oncology care, addressing a significant unmet need in CINV management, particularly for highly emetogenic regimens.
Relatert forskning
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant ant…
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, …
Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial
The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing signif…
Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial
Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight redu…